Dr. Reddy’s Q1 net profit drops 69% to ₹435.6 crore due to lower lenalidomide sales and semaglutide quality issues.

Dr Reddy's FY27 Q1 preview indicates potential earnings pressure, with analysts predicting significant declines in profit and EBITDA.

Dr Reddy's Laboratories reported a 69% fall in Q1 profit to ₹434 crore as lenalidomide transition and semaglutide API impact offset base business growth.